Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor–Associated Acute Kidney Injury: CON
Open Access
- 26 March 2020
- journal article
- editorial
- Published by Wolters Kluwer Health in Kidney360
- Vol. 1 (3) , 162-165
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
This publication has 25 references indexed in Scilit:
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer PatientsAmerican Journal of Kidney Diseases, 2016
- Long–Term Renal Outcomes after Cisplatin TreatmentClinical Journal of the American Society of Nephrology, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor useKidney International, 2014
- Renal biopsy practice: What is the gold standard?World Journal of Nephrology, 2014
- Antibiotics induced acute kidney injury: incidence, risk factors, onset time and outcome.2013
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Significant Acute Kidney Injury Due to Non-steroidal Anti-inflammatory Drugs: Inpatient SettingPharmaceuticals, 2010
- Proton pump inhibitors and the kidney: critical reviewClinical Nephrology, 2007